Coherus Oncology, Inc. Common Stock (CHRS) is a publicly traded Healthcare sector company. As of November 9, 2026, CHRS trades at $0.83 with a market cap of $118.97M and a P/E ratio of -11.72. CHRS moved +1.57% today. Year to date, CHRS is -40.37%; over the trailing twelve months it is -39.03%. Its 52-week range spans $0.71 to $2.62. Analyst consensus is buy with an average price target of $5.50. Rallies surfaces CHRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for CHRS shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $0.83 |
| Market Cap | $118.97M |
| P/E Ratio | -11.72 |
| EPS | $-0.09 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.62 |
| 52-Week Low | $0.71 |
| Volume | 1.97M |
| Avg Volume | 0 |
| Revenue (TTM) | $1.97B |
| Net Income | $-10.28M |
| Gross Margin | 49.54% |
2 analysts cover CHRS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.50.